Empagliflozin in Patients with Chronic Kidney Disease

Empagliflozin in Patients with Chronic Kidney Disease is organized by CEimpact.

Initial Release Date: June 12, 2023
Planned Expiration Date: June 13, 2026
 
Description:
The EMPA-KIDNEY trial assessed the efficacy and safety of empagliflozin in patients with chronic kidney disease. This course discusses the results of the trial and its implication on your patients.

Upon successful completion of this application-based course, participants should be able to:
• Describe the pathophysiology and FDA-approved indications of empagliflozin
• Review the current treatment of chronic kidney disease
• Discuss the strengths, limitations, and results of the EMPA-KIDNEY trial
• Evaluate the role of empagliflozin in the progression of chronic kidney disease
• Apply clinical implications of the EMPA-KIDNEY study to a patient case